Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2004-04-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.2003.010090PMID 15090564PMCID PMC1763573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• Randomized, comparative study of interferon β-1a treatment regimens in MS

  2002cited by this paper
• Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS

  2002cited by this paper
• Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial

  2002cited by this paper
• A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

  2002cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

  2001cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis

  1999cited by this paper
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.

  1999cited by this paper
• Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta‐1a after intramuscular and subcutaneous administration

  1999cited by this paper
• Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta‐1a after intramuscular and subcutaneous administration

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Interferon Therapy of Multiple Sclerosis

  1997cited by this paper
• Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

  1997cited by this paper
• Pharmacokinetics and Pharmacodynamics of Interferon Beta-la (IFNβ-1a) in Healthy Volunteers after Intravenous, Subcutaneous or Intramuscular Administration

  1997cited by this paper
• Acyclovir treatment of relapsing-remitting multiple sclerosis

  1996cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

  1993cited by this paper
• Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis

  1993cited by this paper
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

  1993cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983influential reference
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• Comparative Therapeutic Strategies for Secondary Progressive Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta‐analysis

  2024cites this paper
• Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

  2024cites this paper
• An overview on disease modifying and symptomatic drug treatments for multiple sclerosis

  2024cites this paper
• Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials

  2024cites this paper
• Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK

  2024cites this paper
• Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches

  2023cites this paper
• The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?

  2023cites this paper
• Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials

  2023cites this paper
• Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials

  2022cites this paper
• Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.

  2022cites this paper
• Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways

  2022cites this paper
• Therapie der aktiven sekundär progredienten multiplen Sklerose

  2022cites this paper
• What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?

  2022cites this paper
• Hepatotoxicity case due to interferon beta-1a use

  2022cites this paper
• Management of secondary-progressive multiple sclerosis

  2022cites this paper
• Updates and advances in multiple sclerosis neurotherapeutics

  2022cites this paper
• Comprehensive Assessment of Multiple Sclerosis: From Immunotherapy and Immunopathogenesis to Predictive Biomarkers

  2022influential citation
• Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland

  2021cites this paper
• Disease-modifying treatment of secondary progressive multiple sclerosis

  2021cites this paper
• Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis.

  2021cites this paper
• Advances in the Treatment of Multiple Sclerosis.

  2021cites this paper
• The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review

  2021cites this paper
• Krankheitsmodifizierende Therapie der sekundär progredienten Multiplen Sklerose

  2021cites this paper
• Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

  2020cites this paper
• Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.

  2020cites this paper
• Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis

  2020cites this paper
• Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

  2020cites this paper
• The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

  2020cites this paper
• Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

  2020cites this paper
• The window of opportunity for treatment of progressive multiple sclerosis.

  2020influential citation
• Relating Treatment Effect on Relapses with Disability Worsening in Multiple Sclerosis Patients: Age Matters

  2019cites this paper
• Current immunotherapies for multiple sclerosis and neuromyelitis optica spectrum disorders: the similarities and differences

  2019influential citation
• High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

  2019cites this paper
• Diagnosis and Management of Progressive Multiple Sclerosis

  2019cites this paper
• Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation.

  2019cites this paper
• Diagnosis and management of secondary-progressive multiple sclerosis: time for change.

  2019cites this paper
• Beta interferons and glatiramer acetate for treatment of MS: TA guidance 2018

  2018cites this paper
• ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

  2018cites this paper
• Authorship of phase 3 trials in multiple sclerosis

  2018cites this paper
• Disease-Modifying Treatment in Progressive Multiple Sclerosis

  2018cites this paper
• Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

  2018cites this paper
• Treatment of progressive multiple sclerosis: Challenges and promising perspectives.

  2018cites this paper
• ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

  2018cites this paper
• Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

  2018cites this paper
• Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis

  2018cites this paper
• Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance

  2018cites this paper
• Trials of Licenced RRMS DMTs in Progressive MS

  2018cites this paper
• Sclérose en Plaques : les traitements de fond peuvent-ils être arrêtés après 50 ans en cas de forme inactive de la maladie ?

  2018cites this paper
• Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment.

  2017cites this paper
• Diagnosing secondary progressive multiple sclerosis

  2017cites this paper
• Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: A systematic review.

  2017cites this paper
• Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment

  2017cites this paper
• Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

  2017cites this paper
• Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

  2017cites this paper
• Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

  2017cites this paper
• Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis

  2017cites this paper
• Immunomodulatory Therapy for Multiple Sclerosis

  2017cites this paper
• Progressive MS trials: Lessons learned

  2017cites this paper
• A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

  2016cites this paper
• Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

  2016cites this paper
• MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

  2016cites this paper
• A 10-year follow-up of the European multicenter trial of interferon β1 b in secondary-progressive multiple sclerosis

  2016cites this paper
• Progressive multiple sclerosis: from pathogenic mechanisms to treatment.

  2016cites this paper
• Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis

  2016cites this paper
• Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

  2016cites this paper
• Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis

  2015cites this paper
• Relapses and disability accumulation in progressive multiple sclerosis

  2015cites this paper
• Progressive multiple sclerosis.

  2015cites this paper
• Update on treatments in multiple sclerosis.

  2015cites this paper
• Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

  2015cites this paper
• Progressive multiple sclerosis 3 Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

  2015cites this paper
• A Multimodal Intervention for Patients with Secondary Progressive Multiple Sclerosis: Feasibility and Effect on Fatigue

  2014cites this paper
• Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

  2014cites this paper
• Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study

  2014influential citation
• Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

  2013cites this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cites this paper
• Interferon-β1b in der Multiple-Sklerose-Therapie

  2013cites this paper
• Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments

  2013cites this paper
• Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis

  2013cites this paper
• Disease-modifying treatments for progressive multiple sclerosis

  2013cites this paper
• Disease-modifying treatments for secondary progressive and progressive relapsing multiple sclerosis

  2013cites this paper
• Personalized Management of Multiple Sclerosis

  2013cites this paper
• WITHDRAWN: Guía para el tratamiento de pacientes con esclerosis múltiple: uso de inmunomoduladores e inmunosupresores

  2012cites this paper
• Interferon Beta and Glatiramer Acetate Therapy

  2012cites this paper
• Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis

  2012cites this paper
• Interferon beta for secondary progressive multiple sclerosis.

  2012cites this paper
• Interferon β for secondary progressive multiple sclerosis: a systematic review

  2012influential citation
• Early-Stage Multiple Sclerosis

  2012cites this paper
• Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

  2012cites this paper
• An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients.

  2012cites this paper
• Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

  2011cites this paper
• Targeting Progressive Neuroaxonal Injury

  2011cites this paper
• Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.

  2011cites this paper
• A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

  2011cites this paper
• PRISMS: the story of a pivotal clinical trial series in multiple sclerosis

  2010cites this paper
• Interferon Beta for primary progressive multiple sclerosis.

  2010cites this paper
• Nocebo effects in multiple sclerosis trials: a meta-analysis

  2010cites this paper
• A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

  2010cites this paper
• Interferon beta for primary progressive multiple sclerosis.

  2009cites this paper